Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of VEE TC-83 Vaccine
NCT00582504Phase 2Unknown
- Sponsor
- U.S. Army Medical Research and Development Command
- Start
- Sep 2007
- Primary completion
- Dec 2021
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Venezuelan equine encephalitis vaccine TC-83 in Venezuelan equine encephalomyelitis (VEE), sponsored by U.S. Army Medical Research and Development Command. Primary endpoints: Plaque-Reduction Neutralization Titer 80% and Number of Adverse Events at 7 years. Status: unknown.
02
Drugs
Venezuelan equine encephalitis vaccine TC-83
03
Conditions
Venezuelan equine encephalomyelitis (VEE)
Beyond the preview
Go deeper on NCT00582504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00582504.